Hola,
¿eres nuevo aquí?

Regístrate gratis y conecta tu empresa con financiación pública, partners y proyectos.

Tengo cuenta

Regístrate

Ver video

CANCERALIA

Financiado

Cerrado

Development of novel diagnostic and therapeutic approaches to improve patient ou...

Development of novel diagnostic and therapeutic approaches to improve patient outcome in lung and pancreatic tumours Lung and pancreatic cancers still have a mortality rate over 85% at 5 years of diagnosis, a clear demonstration of the actual treatment failure and the need for improved clinical management. This involves better tools for diagnosi... ver más

30/09/2014

FUNDACION SECTOR P...

4M€

Presupuesto del proyecto: 4M€

Líder del proyecto

FUNDACION SECTOR PUBLICO ESTATAL CENTRO NACIO... No se ha especificado una descripción o un objeto social para esta compañía.

TRL 4-5 | 18M€

Fecha límite participación Sin fecha límite de participación.

Ver 7 Participantes

Financiación concedida El organismo FP7 notifico la concesión del proyecto el día 2014-09-30 No tenemos la información de la convocatoria

0% 72% 100%

Información adicional privada

No hay información privada compartida para este proyecto. Habla con el coordinador.

7 Participantes

FUNDACION SECTOR PUBLICO EST...

0.00€ | Lider

KU Leuven

N.D. | Participante

GEHC

N.D. | Participante

SERMAS

N.D. | Participante

Conecta tu I+D

¿Tienes un proyecto y buscas un partner? Gracias a nuestro motor inteligente podemos recomendarte los mejores socios y ponerte en contacto con ellos. Te lo explicamos en este video

Proyectos interesantes

CANCERINNOVATION Using novel methodologies to target and image cancer invasio... 2M€ Cerrado

SYSBIODREZ SYSTEMS BIOLOGY APPROACH TO PREDICTING OUTCOMES OF LUNG CANC... 270K€ Cerrado

PDC2022-133865-I00 DESARROLLO DE DOS PROTOTIPOS PRECOMPETITIVOS PARA EL SEGUIMI... 127K€ Cerrado

CAPER/BREAST CANCE CAPER in Invasive Breast Cancer 2M€ Cerrado

CAREMORE Cancer Responsiveness Monitoring based on Resistance mutatio... 7M€ Cerrado

ImOPac GemciTest An innovative In Vitro Diagnostic for the decisio... 71K€ Cerrado

Líder del proyecto

FUNDACION SECTOR PUBLICO ESTATAL CENTRO NACIO... No se ha especificado una descripción o un objeto social para esta compañía.

TRL 4-5 | 18M€

Presupuesto del proyecto 4M€

Fecha límite de participación Sin fecha límite de participación.

Descripción del proyecto Lung and pancreatic cancers still have a mortality rate over 85% at 5 years of diagnosis, a clear demonstration of the actual treatment failure and the need for improved clinical management. This involves better tools for diagnosis, prognosis, and selection of sensitive and resistant patients to current conventional therapies or improved innovative treatments as well as the development of novel therapeutic strategies. The major objective of this proposal is to improve management of patients with either lung or pancreatic tumors by studying the clinical applications of still not investigated metabolic and signalling pathways with the following aims: -development of new tools for early diagnosis -identification of novel tumour markers for early diagnosis and prognosis -prediction of response to conventional treatments -identification of the molecular mechanisms of generation of resistance -development of improved treatments based on the identification of novel molecular targets -design of novel anticancer strategies. -achieve a better understanding of how combinatorial treatments using current standard clinical procedures with novel treatments under development may improve patient outcome. The proposed consortium is composed of four experimental research groups with a profound knowledge on molecular and cellular biology of cancer, and ample experience in the design of targeted and personalized cancer therapies along with translational research, complemented with three clinical groups with an extensive experience in the clinical management of lung and pancreatic cancer patients, guaranteeing a clinical proof-of principle and applicability, integrating basic-clinical European scientific excellence. Furthermore, the consortium has incorporated one company with direct involvement in critical areas that will make feasible to translate to the clinic the results generated in the project.

Conecta tu I+D

Entra hoy

¿Olvidé mi contraseña?

Financiación

Empresas

CTIs/Universidades

Proyectos

Investigadores